ClinicalTrials.gg
CompletedNCT00625313HMYUpdated Oct 2, 2026

Clinical Study of a UV-Absorbing Acrylic Posterior Chamber Intraocular Lens

An interventional study of HMY Model YA-60BB IOL in Aphakia, sponsored by Hoya Surgical Optics, Inc.. Completed at 1 site in United States. Open to participants aged 21 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Hoya Surgical Optics, Inc. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
617
Allocation
Not applicable
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Aphakia with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Aphakia · United States.

Enrollment
2nd of 23
617 · median 155
Started
2004
with 1 other
No phase
21 of 29
1 open now
Registered
2nd of 29
by date
Lead sponsor
3 of 29
Hoya Surgical Optics, Inc.

Among the 29 studies in Aphakia with a site in United States, this one is the 2nd largest by enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2004, is one of 21 with no phase, and was the 2nd registered.

Aphakia

69 studies on the registry are indexed under Aphakia; 6 are open to participants now.

Browse Aphakia studies →

Open to participants now

2 of the 29 studies in Aphakia with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Aphakia studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 21 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Aphakia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and efficacy of the HMY Model YA-60BB Intraocular Lens (IOL) when implanted in the posterior chamber of the human eye for the optical correction of aphakia following cataract extraction.

Read the detailed description

A prospective, single-phase, non-randomized, open-label study to include patients with operable cataract of the human crystalline lens who have a potential post-operative best corrected visual acuity of 20/40 or better and no pre-existing progressive sight-threatening ocular disorders. Patients who are eligible per inclusion / exclusion criteria will undergo phacoemulsification cataract extraction and then implantation of the Hoya HMY Model YA-60BB posterior chamber intraocular lens. Each patient will be followed-up at specific time intervals to assess safety and effectiveness, for up to 36 months.

03

Conditions studied

  • Aphakia

Browse trials for

Keywords

  • Cataract
  • aphakia
  • intraocular lens
  • IOL
  • Optical correction of aphakia
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult patients with cataract who are eligible for phacoemulsification cataract extraction of the lens through an incision of approximately 4 mm, and primary implantation of a posterior chamber intraocular lens.
  2. Patients must have no pre-existing ocular conditions that preclude the ability of the treated eye to achieve BCVA of 20/40 or better after IOL implantation.
  3. Patients must be at least 21 years of age.
  4. Patients must sign a written form.
  5. Patients must be able and willing to return for scheduled follow-up examinations after surgery throughout the 36 month study.

Exclusion criteria

Exclusion Criteria:

  1. Patients with a history of/or clinical signs of any of the following sight-threatening conditions:

    1. Previous Retinal Detachment or retinal pathology in operative eye, only
    2. Macular Degeneration in either eye
    3. Macular Edema in either eye
    4. Persistent Iritis/Uveitis in operative eye, only
  2. Uncontrolled Glaucoma or under current treatment for glaucoma in either eye
  3. Significant Corneal Disease in operative eye, only
  4. Proliferative Diabetic Retinopathy in either eye
  5. Patients who have had previous ocular surgery, of any kind, within the last 6 months or patients who have had previous ocular surgery at any time and who do not have potential BCVA after cataract extraction/IOL implantation of 20/40 or better
  6. Patients who have best corrected vision worse than 20/200 in the fellow eye.
  7. Patients with serious (i.e., life threatening) non-ophthalmic disease which may preclude study completion.
  8. Patients who have undergone previous cataract extraction and intraocular lens implantation.
  9. Patients unwilling or unable to sign the IRB-approved document for the study or who cannot or will not complete the study's examination schedule.
  10. Patients who are currently enrolled in another clinical trial, or who exited a clinical trial within the last 30 days.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
617 participants (actual)

Study arms

  • Experimental
    HMY Model YA-60BB IOL

    Patients receiving a Hoya HMY Acrylic Foldable Intraocular Lens.

    Device: HMY Model YA-60BB IOL

Interventions

  • DeviceHMY Model YA-60BB IOL

    Following phacoemulsification cataract extraction, insertion of a Hoya HMY posterior chamber intraocular lens will be performed.

    Also known as: Hoya HMY Acrylic Foldable Intraocular Lens

06

What researchers measure

Primary outcomes

  1. Best Corrected Visual Acuity

    Time frame: 12 months postoperative

Secondary outcomes

  1. Adverse events/complications

    Time frame: 12 months postoperative

07

Study locations

1 site
  • Contact Hoya Surgical Optics, Inc. for Trial Locations
    Chino Hills, California 91709, United States
08

Timeline

1 registry update since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2004, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2008
First posted
Feb 28, 2008
Start
Mar 2004
Primary completionActual
Dec 2008
CompletionActual
Dec 2008
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: index terms
1 update, last Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Minor edits only
    + 1 other change: index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT00625313
Lead sponsor
Hoya Surgical Optics, Inc.
Responsible party
Sponsor
First posted
Feb 28, 2008
Start date
Mar 2004
Primary completion
Dec 2008
Completion
Dec 2008
Last update
Oct 2, 2026

Study contacts

Steven L. Ziemba, M. Sc
study chair · Hoya Surgical Optics / Fullerton Regulatory & Clinical

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion